E
Elizabeth I. Buchbinder
Researcher at Harvard University
Publications - 98
Citations - 7625
Elizabeth I. Buchbinder is an academic researcher from Harvard University. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 24, co-authored 66 publications receiving 5254 citations. Previous affiliations of Elizabeth I. Buchbinder include Beth Israel Deaconess Medical Center & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott,Zhuting Hu,Derin B. Keskin,Derin B. Keskin,Sachet A. Shukla,Sachet A. Shukla,Jing Sun,David J. Bozym,Wandi Zhang,Adrienne M. Luoma,Anita Giobbie-Hurder,Lauren Peter,Christina Chen,Oriol Olive,Todd A. Carter,Shuqiang Li,David J. Lieb,Thomas Eisenhaure,Evisa Gjini,Jonathan Stevens,William J. Lane,Indu Javeri,Kaliappanadar Nellaiappan,Andres M. Salazar,Heather Daley,Michael S. Seaman,Elizabeth I. Buchbinder,Elizabeth I. Buchbinder,Charles H. Yoon,Maegan Harden,Niall J. Lennon,Stacey Gabriel,Scott J. Rodig,Scott J. Rodig,Dan H. Barouch,Dan H. Barouch,Dan H. Barouch,Jon C. Aster,Jon C. Aster,Gad Getz,Gad Getz,Kai W. Wucherpfennig,Donna Neuberg,Jerome Ritz,Jerome Ritz,Eric S. Lander,Eric S. Lander,Edward F. Fritsch,Edward F. Fritsch,Nir Hacohen,Nir Hacohen,Catherine J. Wu +51 more
TL;DR: The feasibility, safety, and immunogenicity of a vaccine that targets up to 20 predicted personal tumour neoantigens is demonstrated and a strong rationale for further development of this approach, alone and in combination with checkpoint blockade or other immunotherapies is provided.
Journal ArticleDOI
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
TL;DR: An overview of the CTLA-4 and PD-1 pathways and implications of their inhibition in cancer therapy is provided and the clinical profiles of immuno-oncology agents inhibiting these 2 checkpoints may vary based on their mechanistic differences.
Journal ArticleDOI
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby-Arnon,Parin Shah,Michael S. Cuoco,Christopher Rodman,Mei-Ju Su,Johannes C. Melms,Rachel Leeson,Abhay Kanodia,Shaolin Mei,Jia-Ren Lin,Shu Wang,Bokang Rabasha,David Liu,Gao Zhang,Claire Margolais,Orr Ashenberg,Patrick A. Ott,Elizabeth I. Buchbinder,Rizwan Haq,F. Stephen Hodi,Genevieve M. Boland,Ryan J. Sullivan,Dennie T. Frederick,Benchun Miao,Tabea Moll,Keith T. Flaherty,Meenhard Herlyn,Russell W. Jenkins,Rohit Thummalapalli,Monika S. Kowalczyk,Israel Cañadas,Bastian Schilling,Bastian Schilling,Adam N.R. Cartwright,Adrienne M. Luoma,Shruti Malu,Patrick Hwu,Chantale Bernatchez,Marie Andrée Forget,David A. Barbie,Alex K. Shalek,Itay Tirosh,Peter K. Sorger,Kai W. Wucherpfennig,Eliezer M. Van Allen,Dirk Schadendorf,Bruce E. Johnson,Asaf Rotem,Asaf Rotem,Orit Rozenblatt-Rosen,Levi A. Garraway,Charles H. Yoon,Charles H. Yoon,Benjamin Izar,Aviv Regev +54 more
TL;DR: A resistance program expressed by malignant cells that is associated with T cell exclusion and immune evasion is identified, and this study provides a high-resolution landscape of ICI-resistant cell states, identifies clinically predictive signatures, and suggests new therapeutic strategies to overcome immunotherapy resistance.
Journal ArticleDOI
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson,Ryan J. Sullivan,Patrick A. Ott,Matteo S. Carlino,Nikhil I. Khushalani,Fei Ye,Alexander Guminski,Igor Puzanov,Donald P. Lawrence,Elizabeth I. Buchbinder,Tejaswi V. Mudigonda,Kristen Spencer,Carolin Bender,Jenny H. Lee,Howard L. Kaufman,Alexander M. Menzies,Jessica C. Hassel,Janice M. Mehnert,Jeffrey A. Sosman,Georgina V. Long,Joseph I. Clark +20 more
TL;DR: Ipilimumab was clinically active and was associated with exacerbations of autoimmune disease and conventional ipILimumab-induced irAEs that were readily manageable with standard therapies when started in a timely fashion.
Journal ArticleDOI
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
Jeffrey S. Weber,Geoff Gibney,Ryan J. Sullivan,Jeffrey A. Sosman,Craig L. Slingluff,Donald P. Lawrence,Theodore F. Logan,Lynn M. Schuchter,Suresh G. Nair Md,Leslie A. Fecher,Leslie A. Fecher,Elizabeth I. Buchbinder,Elmer Berghorn,Mary Ruisi,George Kong,Joel Jiang,Christine Horak,F. Stephen Hodi +17 more
TL;DR: In this paper, the authors evaluated whether sequential administration of nivolumab followed by ipilimumab, or the reverse sequence, could improve safety without compromising efficacy in patients with advanced melanoma.